TAT and cardiovascular disorder: Since Tat is produced and released even during cART [52,98], all of the above data indicate that the interaction between eTat and the αvβ3, αvβ5 and α5β1 integrins may exacerbate endothelial dysfunction while increasing the risk of cardiovascular diseases in treated patients, with implications for novel Tat-based therapeutic approaches.